Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AstraZeneca | 8.83% | $241.34M | £192.33B | 7.56% | 75 Outperform | |
| HSBC Holdings | 7.90% | $216.05M | £180.66B | 47.15% | 79 Outperform | |
| Shell (UK) | 7.50% | $205.02M | £163.15B | 14.14% | 77 Outperform | |
| Unilever | 5.16% | $141.17M | £113.55B | -3.12% | 77 Outperform | |
| Rolls-Royce Holdings | 4.29% | $117.22M | £96.40B | 109.38% | 71 Outperform | |
| British American Tobacco | 3.66% | $100.12M | £85.53B | 47.84% | 60 Neutral | |
| BP p.l.c. | 3.11% | $84.98M | £66.64B | 14.36% | 57 Neutral | |
| GlaxoSmithKline | 3.02% | $82.64M | £66.07B | 13.26% | 77 Outperform | |
| RELX plc | 2.90% | $79.20M | £63.66B | -0.37% | 79 Outperform | |
| Rio Tinto | 2.71% | $74.05M | £92.19B | 5.40% | 79 Outperform |